IMR Press / EJGO / Volume 34 / Issue 2 / pii/1630905776181-1626694685

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Bevacizumab for the treatment of recurrent ovarian cancer: a retrospective cohort study
Show Less
1 Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY
2 Department of Pharmacy, Roswell Park Cancer Institute, Buffalo, NY
3 Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, NY (USA)
Eur. J. Gynaecol. Oncol. 2013, 34(2), 113–119;
Published: 10 April 2013

Objective: To determine response rates (RR), progression-free survival (PFS), overall survival (OS), and toxicity in patients treated with cytotoxic chemotherapy, in combination with bevacizumab compared to cytotoxic chemotherapy alone, in the setting of recurrent ovarian cancer. Materials and Methods: After obtaining Institutional Review Board approval, two cohorts of patients with recurrent ovarian cancer were identified: 1) patients that received cytotoxic chemotherapy with bevacizumab from January 2006 to June 2009; 2) patients that received cytotoxic chemotherapy alone. RR were measured using RECIST criteria or by CA-125 levels using modified Rustin criteria. RR, OS, and PFS were determined using Kaplan-Meier survival analysis. Results: Thirty-two patients that received bevacizumab in combination with cytotoxic chemotherapy and 32 patients that received cytotoxic chemotherapy alone were identified. The control patients were matched for age, platinum response, histology, surgical outcome, grade, and number of previous chemotherapy regimens. There were no differences between the two cohorts in the rates of venous thromboembolism (VTE) (p = 0.39), bleeding (p = 0.15) or bowel obstruction (p = 0.40). The rate of hypertension in the bevacizumab cohort was greater than in the comparison cohort (p < 0.005). There were no differences in response rates PR/CR vs SD/PD (p = 0.46), OS (p = 0.79) or PFS (p = 0.43). Conclusions: With increased toxicity, increased cost of therapy and no improvement in PFS or OS, the role of bevacizumab in patients with recurrent ovarian cancer warrants further investigation.
Squamous cell carcinoma
Endometrial carcinoma
Ichthyosis uteri
Ovarian cancer
Back to top